Advertisement

Chemoprevention Trials for Prostate Cancer

  • Peter Greenwald
  • Ronald Lieberman
Part of the Contemporary Cancer Research book series (CCR)

Abstract

Prostate cancer is the fourth most frequent cancer among men worldwide (40). Given the magnitude of the prostate cancer burden, considerable efforts have been made by the scientific research community to improve our understanding of the factors that contribute to prostate cancer risk and to develop approaches to modify those factors. Age, race, family history, and the presence of certain genetic polymorphisms, all are risk factors for prostate cancer that clearly cannot be modified (13). Prostate cancer incidence increases dramatically with age (46); in the United States, African-American men are at greater risk than whites (46). Heritable effects may account for as much as one-third of prostate cancer risk (1); and genetic polymorphisms in the vitamin D receptor (24,25,52), the androgen receptor (24), N-acetyltransferase (NATI) (16), and certain glutathione S-transferases (GSTs) (45) likely contribute to variations in prostate cancer risk among individuals. Hormones—both sex hormones and insulin-like growth factors (particularly IGF-I)—may also influence the risk of prostate cancer. Evidence indicates that cumulative exposure of the prostate to androgens—including testosterone and dihydrotestosterone (DHT)—contributes to prostate cancer development (9,57).

Keywords

Prostate Cancer Prostate Specific Antigen Prostate Cancer Risk Prostate Cancer Incidence Chemoprevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahlbom, A., P. Lichtenstein, H. Malmstrom, M. Feychting, K. Hemminki, and N. L. Pedersen. 1997. Cancer in twins: genetic and nongenetic familial risk factors. J. Natl. Cancer Inst. 89: 287–293.PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous. 1997. A catalog of cancer genes at the click of a mouse. Science 276: 1023–1024.CrossRefGoogle Scholar
  3. 3.
    Bacus, J. W. and J. V. Bacus. 1994. Quality control in image cytometry, DNA ploidy. J. Cell. Biochem. 19: 153–164.Google Scholar
  4. 4.
    Bartels, P. A. 1992. Computer-generated diagnoses and usage analysis: an overview. Cancer 69: 1636–1638.PubMedCrossRefGoogle Scholar
  5. 5.
    Boone, C. W., J. W. Bacus, V. E. Steele, and G. J. Kelloff. 1997. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate endpoints for clinical trials. Proc. Soc. Exp. Biol. Med. 216: 151–165.PubMedGoogle Scholar
  6. 6.
    Bostwick, D. G. 1995. High-grade prostatic intraepithelial neoplasia. Cancer 75: 1823–1826.CrossRefGoogle Scholar
  7. 7.
    Boyle, P., P. Maisonneuve, and P. Napalkov. 1995. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46: 47–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Byar, D. and S. Piantadosi. 1985. Factorial designs for randomized clinical trials. Cancer Treat. Rep. 69: 1055–1063.PubMedGoogle Scholar
  9. 9.
    Chan, J. M., M. J. Stampfer, and E. L. Giovannucci. 1998. What causes prostate cancer? A brief summary of the epidemiology. Semin. Cancer Biol. 8: 263–273.PubMedCrossRefGoogle Scholar
  10. 10.
    Clark, L. C., B. Dalkin, A. Krongrad, G. F. Combs, Jr., B. W. Turnbull, E. H. Slate, et al. 1998. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 81: 730–734.PubMedCrossRefGoogle Scholar
  11. 11.
    Cote, R. J., E. C. Skinner, C. E. Salem, S. Mertes, F. Z. Stanczyk, B. Henderson, et al. 1998. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br. J. Cancer 78: 413–418.PubMedCrossRefGoogle Scholar
  12. 12.
    Cronin, R. A., L. S. Freedman, R. Lieberman, A. L. Weiss, S. W. Beenken, and G. J. Kelloff. 1999. Bayesian monitoring of Phase II trials in cancer chemoprevention. J. Clin. Epidemiol. 52: 705–711.PubMedCrossRefGoogle Scholar
  13. 13.
    Cussenot, O., A. Valeri, P. Berthon, G. Fournier, and P. Mangin. 1998. Hereditary prostate cancer and other genetic predispositions to prostate cancer. Urol. Int. 60: 30–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Duggan, D. J., M. Bittner, Y. Chen, and P. Meltzer. 1999. Expression profiling using cDNA microarrays. Nat. Genet. 21 (Suppl.): 10–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Feigl, P., B. Blumenstein, I. Thompson, J. Crowley, M. Wolf, B. S. Kramer, et al. 1995. Design of the Prostate Cancer Prevention Trial (PCPT). Control. Clin. Trials 16: 150–163.PubMedCrossRefGoogle Scholar
  16. 16.
    Fukutome, K., M. Watanabe, T. Shiraishi, M. Murata, H. Uemura, Y. Kubota, et al. 1999. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett. 136: 83–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Gann, P. H., J. Ma, E. Giovannucci, W. Willett, F. M. Sacks, C. H. Hennekens, and M. J. Stampfer. 1999. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59: 1225–1230.PubMedGoogle Scholar
  18. 18.
    Giovannucci, E. 1998. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 9: 567–582.PubMedCrossRefGoogle Scholar
  19. 19.
    Giovannucci, E. 1999. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 91: 317–331.PubMedCrossRefGoogle Scholar
  20. 20.
    Giovannucci, E., E. B. Rimm, A. Wolk, A. Ascherio, M. J. Stampfer, G. Colditz, et al. 1998. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 58: 442–447.PubMedGoogle Scholar
  21. 21.
    Haenszel, W. and M. Kurihara. 1968. Studies of Japanese migrants: I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst. 40: 43–68.PubMedGoogle Scholar
  22. 22.
    Hartman, T. J., D. Albanes, P. Pietinen, A. M. Hartman, M. Rautalahti, J. Tangrea, et al. 1998. The association between baseline vitamin E, selenium, and prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol. Biomark. Prey. 7: 335–340.Google Scholar
  23. 23.
    Heinonen, O. P., D. Albanes, J. Virtamo, P. R. Taylor, J. K. Huttunen, A. Hartman, et al. 1998. Prostate cancer and supplementation with a-tocopherol and 0-carotene: Incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 90: 440–446.PubMedCrossRefGoogle Scholar
  24. 24.
    Ingles, S. A., R. K. Ross, M. C. Yu, R. A. Irvine, G. La Pera, R. W. Haile, et al. 1997. Association of prostate cancer risk with genetic polymorphisme in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 89: 166–170.PubMedCrossRefGoogle Scholar
  25. 25.
    Ingles, S. A., G. A. Coetzee, R. K. Ross, B. E. Henderson, L. N. Kolonel, L. Crocitto, et al. 1998. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 58: 1620–1623.PubMedGoogle Scholar
  26. 26.
    Jacobsen, B. K., S. F. Knutsen, and G. E. Fraser. 1998. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9: 553–557.PubMedCrossRefGoogle Scholar
  27. 27.
    Keetch, D. W., W. J. Catalona, and D. S. Smith. 1994. Serial prostate biopsies in men with persistently elevated serum prostate-specific antigen values. J. Urol. 151: 1571–1574.PubMedGoogle Scholar
  28. 28.
    Kelloff, G. J., R. Lieberman, M. K. Brawer, E. D. Crawford, F. Labrie, and G. J. Miller. 1999. Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostate Diseases 2: 27–33.CrossRefGoogle Scholar
  29. 29.
    Kelloff, G. J., R. Lieberman, V. E. Steele, C. W. Boone, R. A. Lubet, L. Kopelovitch, et al. 1999. Chemoprevention of prostate cancer: concepts and strategies. Eur. Urol. 35: 342–350.Google Scholar
  30. 30.
    Kolonel, L. N., A. M. Y. Nomura, and R. V. Cooney. 1999. Dietary fat and prostate cancer: current status (review). J. Natl. Cancer Inst. 91: 414–428.PubMedCrossRefGoogle Scholar
  31. 31.
    Kurhanewicz, J., D. B. Vigneron, H. Hricak, P. Narayan, P. Carroll, and S. Nelson. 1996. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198: 795–805.PubMedGoogle Scholar
  32. 32.
    Lee, M. M., R.-T. Wang, A. W. Hsing, F.-L. Gu, T. Wang, and M. Spitz. 1998. Case-control study of diet and prostate cancer in China. Cancer Causes Control 9: 545–552.PubMedCrossRefGoogle Scholar
  33. 33.
    Lieberman, R., J. A. Crowell, E. T. Hawk, C. W. Boone, C. C. Sigman, and G. J. Kelloff. 1998. Development of new cancer chemopreventive agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin. Chem. 44: 420–427.PubMedGoogle Scholar
  34. 34.
    Lieberman, R., J. Thompson, H. Akaza, P. Greenwald, and W. Fair. 1999. Progress in new chemopreventive agent development for prostate cancer prevention: modulators of promotion and progression. Prostate Cancer and Prostate Diseases (in press).Google Scholar
  35. 35.
    McCormick, D. L., K. V. N. Rao, M. C. Bosland, V. E. Steele, R. A. Lubet, and G. J. Kelloff. 1995 Inhibition of rat prostatic carcinogenesis by dietary dehydroepiandrosterone but not by N-(4-hydroxy-phenyl)-all-trans-retinamide. Proc. Am. Assoc. Cancer Res. 36: 126.Google Scholar
  36. 36.
    McCormick, D. L., K. V. N. Rao, L. Dooley, V. E. Steele, R. A. Lubet, G. Kelloff, et al. 1998. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-transretinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. 58: 3282–3288.PubMedGoogle Scholar
  37. 37.
    McCormick, D. L., K. V. N. Rao, V. E. Steele, R. A. Lubet, G. J. Kelloff, and M. C. Bosland. 1999. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 59: 521–524.PubMedGoogle Scholar
  38. 38.
    Messing, E. M., R. R. Love, K. D. Tutsch, A. K. Verma, J. Douglas, M. Pomplun, et al. 1999. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J. Natl. Cancer Inst. 91: 1416–1417.PubMedCrossRefGoogle Scholar
  39. 39.
    Muir, C. S., J. Nectoux, and J. Staszewski. 1991. The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta. Oncol. 30: 133–140.PubMedCrossRefGoogle Scholar
  40. 40.
    Parkin, D. M., P. Pisani, and J. Ferlay. 1999. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80: 827–841.PubMedCrossRefGoogle Scholar
  41. 41.
    Pound, C. R., A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. Walsh. C. 1999. Natural history of progression after PSA elevation following radical prostatectomy. DAMA 281: 1591–1597.Google Scholar
  42. 42.
    Prentice, R. 1989. Surrogate endpoints in clinical trials: definitive operational criteria. Stat. Med. 8: 431–442.PubMedCrossRefGoogle Scholar
  43. 43.
    Rao, K. V. N., D. L. McCormick, M. C. Bosland, V. E. Steele, R. A. Lubet, and G. J. Kelloff. 1996. Chemopreventive efficacy evaluation of liarozole fumarate, difluoromethylornithine, and oltipraz in the rat prostate. Proc. Am. Assoc. Cancer Res. 37: 273.Google Scholar
  44. 44.
    Rao, K. V. N., M. C. Bosland, R. A. Lubet, V. E. Steele, G. J. Kelloff, and D. L. McCormick. 1997. Inhibition of rat prostate carcinogenesis by delayed administration of dehydroepiandrosterone. Proc. Am. Assoc. Cancer Res. 38: 580.Google Scholar
  45. 45.
    Rebbeck, T. R., A. H. Walker, J. M. Jaffe, D. L. White, A. J. Wein, and S. B. Malkowicz. 1999. Glutathione S-transferase-µ (GSTMI) and -0 (GSTMI) genotypes in the etiology of prostate cancer. Cancer Epidemiol. Biomark. Prey. 8: 283–287.Google Scholar
  46. 46.
    Ries, L. A. G., C. L. Kosary, B. F. Hankey, B. A. Miller, L. Clegg, and B. K. Edwards. 1999. SEER Cancer Statistics Review, 1973–1996. National Cancer Institute, Bethesda, MD.Google Scholar
  47. 47.
    Roberts, R. O., E. J. Bergstralh, S. K. Katusic, M. M. Lieber, and S. J. Jacobsen. 1999. Decline in prostate cancer mortality from 1980 to 1997, and an update in incidence trends in Olmsted County, Minnesota. J. Urol. 16: 529–533.Google Scholar
  48. 48.
    Sakr, W. A., G. P. Haas, B. F. Cassin, J. E. Pontes, and J. D. Crissman. 1993. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150: 379–385.PubMedGoogle Scholar
  49. 49.
    Shimizu, H., R. K. Ross, L. Bernstein, R. Yatani, B. E. Henderson, and T. M. Mack. 1991. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63: 963–966.PubMedCrossRefGoogle Scholar
  50. 50.
    Strausberg, R., C. A. Dahl, and R. D. Klausner. 1997. New opportunities for uncovering the molecular basis of cancer. Nat. Genetics 15: 415–416.CrossRefGoogle Scholar
  51. 51.
    Strom, S. S., Y. Yamamura, C. M. Duphorne, M. R. Spitz, R. J. Babaian, P. Pillow, et al. 1999. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr. Cancer 33: 20–25.PubMedCrossRefGoogle Scholar
  52. 52.
    Taylor, J. A., A. Hirvonen, M. Watson, G. Pittman, J. L. Mohler, and D. A. Bell. 1996. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 56: 4108–4110.PubMedGoogle Scholar
  53. 53.
    Thompson, I. M., C. A. Coltman, O. W. Brawley, and A. Ryan. 1995. Chemoprevention of prostate cancer. Semin. Urol. 13: 122–129.PubMedGoogle Scholar
  54. 54.
    Urban, D., R. Myers, U. Manne, H. Weiss, J. Mohler, D. Perkins, et al. 1999. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur. Urol. 35: 429–438.PubMedCrossRefGoogle Scholar
  55. 55.
    van der Meijden, A. P. M. 1999. Practical aspects of clinical trials on chemoprevention of prostate cancer. Eur. Urol. 35: 515–518.PubMedCrossRefGoogle Scholar
  56. 56.
    Veltrie, R. W., M. C. Miller, A. W. Partin, D. S. Coffey, and J. I. Epstein. 1996. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 48: 685–691.CrossRefGoogle Scholar
  57. 57.
    Yip, I., W. Aronson, and D. Heber. 1996. Nutritional approaches to the prevention of prostate cancer progression, in Dietary Fats, Lipids, Hormones, and Tumorigenesis ( Heber, D. and D. Kritchevsky, eds.), Plenum Press, NY, pp. 173–181.Google Scholar
  58. 58.
    Yoshizawa, K., W. C. Willett, S. J. Morris, M. J. Stampfer, D. Spiegelman, E. Rimm, et al. 1998. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl. Cancer Inst. 90: 1219–1224.PubMedCrossRefGoogle Scholar
  59. 59.
    Yu, H., R. E. Harris, Y.-T. Gao, R. Gao, and E. L. Wynder. 1991. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China, versus the United States. Int. J. Epidemiol. 20: 76–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Peter Greenwald
  • Ronald Lieberman

There are no affiliations available

Personalised recommendations